Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. - Wikidata - wikimedia - TriplyDB

Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

http://www.wikidata.org/entity/Q34285683

about

Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination Granulomas and Inflammation: Host-Directed Therapies for Tuberculosis.Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious Diseases Novel therapies for the treatment of pertussis disease Cell death and autophagy in tuberculosis New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics Statin Therapy Is Associated with Reduced Risk of Peptic Ulcer Disease in the Taiwanese Population.Advancing host-directed therapy for tuberculosis.Autophagy in the fight against tuberculosis.Targeting Batf2 for infectious diseases and cancer.Sphingosine-1-phosphate Receptor Agonism Reduces Bordetella pertussis-mediated Lung Pathology High Prevalence and Heterogeneity of Diabetes in Patients With TB in South India: A Report from the Effects of Diabetes on Tuberculosis Severity (EDOTS) Study Is There Potential for Repurposing Statins as Novel Antimicrobials?Statin adjunctive therapy shortens the duration of TB treatment in mice.Effects of Lipid-Lowering Drugs on Vancomycin Susceptibility of Mycobacteria Potential effect of ezetimibe against Mycobacterium tuberculosis infection in type II diabetes.Host-Directed Therapeutic Strategies for Tuberculosis.Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials.The Macrophage: A Disputed Fortress in the Battle against Mycobacterium tuberculosis.

P2860

Q26746099-0C1EF572-F076-4C22-89D0-8B1366E0773C Q26823503-3D892104-DEB3-44E5-A00B-7538515C3E2C Q28074536-7C3976B6-258A-4391-A01E-9157EEBC384B Q28076037-7EAC42EC-526C-44FF-B0FD-CB6C08513B05 Q28081001-F4C87E75-E4B3-4C98-B39C-D0F2C220E697 Q28084039-87404CB6-B31D-4DCB-8BE0-86DB687B3DD2 Q28387214-55BA6275-58F2-4EE4-8EB8-82A3FB547F64 Q30371980-E1BE30BF-7DA3-4C64-85D8-E26A66A68B6A Q33612306-507F59C5-9E91-4459-880A-CF51278A3CE4 Q34466861-2ADDD9FF-463C-4B31-87A8-4E32A7EEFE71 Q35322096-28024920-1B25-4463-A500-8767231BAD60 Q36413539-3EC7A17D-7E8D-4ED7-96A3-AA0DEB4746E3 Q36812849-35A533C1-8A15-4DF4-9016-DD7EFF2EA01A Q37094652-CEA7D440-E7F0-4258-909A-69895C587D65 Q37203857-59189A31-2AF5-49A6-96AF-7EC15869929F Q37223747-0308E6EB-4EA4-4B21-B099-76432C2E89EA Q37287716-623DB898-8405-4B85-97C9-80D8E6A23585 Q40438875-A536A9A9-DE77-4C75-AE55-3CC362EA0E7B Q45006012-AE108344-79D6-4900-B105-67C510BEE54C Q48171420-D0B838E4-16DD-470B-ABE6-7549EEBE9C97 Q49637506-43181565-2AE0-43E5-9E1A-704D7AFE2AC3

P2860

Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

http://www.wikidata.org/entity/Q34285683

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

@ast

Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

@en

Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

@nl

type

label

Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

@ast

Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

@en

Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

@nl

prefLabel

Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

@ast

Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

@en

Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

@nl

P1433

Q34285683-3EEAC5BF-DE04-4166-B9C3-DA92BC603A50

P1476

Q34285683-6EB6AACE-F1DF-459C-AE6B-2A030800C2DD

P2093

Q34285683-1E62086F-55FF-4AC3-8E32-667D2C4EEDBC

Q34285683-307E36BB-0BC6-440A-8AA1-5E1A54E6B53A

Q34285683-3A458CD5-1F8D-4BBE-BA39-E481604EE1BF

Q34285683-714A4A7C-C721-4C2A-9B7A-2024A61EAA02

Q34285683-DAFCD2C9-FE81-45E5-8189-E6AF262E2496

Q34285683-E1EE3476-EAD1-4FF7-BB2D-CB2A6FD08030

P2860

Q34285683-0CCE5552-1F1E-4533-A901-42B56F033467

Q34285683-14888F33-1442-45B9-A9A2-DBB0AF5E7D94

Q34285683-19DA7490-2B73-4AA7-BD54-082DC5D6F43A

Q34285683-1FCC853F-5FA6-4651-B1BF-7BCDBD8828D8

Q34285683-38F72846-8F5A-4412-BCFA-23F7FF75E3E8

Q34285683-3A46172C-F531-475B-AA79-D0466167C6AB

Q34285683-40BC2911-AE6D-4820-903E-0791AE7ECE2C

Q34285683-41147448-D427-4B16-B070-9168F46763EC

Q34285683-45EAA98F-B203-4FA4-910A-7A89A50D5BD9

Q34285683-4A16A2CF-5E1A-4850-A815-F70BC86133A6

P304

Q34285683-1F625161-0AEF-41B6-9132-8C80F8B91692

P31

Q34285683-A8BE194D-3F67-47F6-B32B-A5B0C2BBB2BE

P356

Q34285683-D82C8A33-B8D6-455A-A965-96E40C7F9594

P407

Q34285683-504E1291-E143-4810-B60A-53ED80B080E7

P433

Q34285683-DA246A47-106E-43DA-8F2B-AA99CDA8D024

P478

Q34285683-F1A5AF6A-FC79-4984-9473-6B2F00515397

P577

Q34285683-9A4311B1-BC70-4C15-91B6-62A96402F858

P698

Q34285683-C459AD2C-6F3D-4F04-AA4A-138C4EE5125F

P921

Q34285683-1BE5C5C2-CDFE-494D-A6FC-925F390809CA

P932

Q34285683-6D0BCF0F-733B-4E32-8C3A-16E0862BDF4C

P356

P1433

Journal of Antimicrobial Chemotherapy

P1476

Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

@en

P2093

Ciaran Skerry

http://www.w3.org/2001/XMLSchema#string

Maria L Gennaro

http://www.w3.org/2001/XMLSchema#string

Michael L Pinn

http://www.w3.org/2001/XMLSchema#string

Natalie Bruiners

http://www.w3.org/2001/XMLSchema#string

Petros C Karakousis

http://www.w3.org/2001/XMLSchema#string

Richard Pine

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs

Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice

Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages

Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas

Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis

Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome.

Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence

Effect of simvastatin, an established lipid-lowering drug, on pulmonary Chlamydia pneumoniae infection in mice.

Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models

Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation

P304

2453-2457

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKU166

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24855121

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

4184365

http://www.w3.org/2001/XMLSchema#string